FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2003. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3635452013 | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | en | Definition | Active | Entire term case sensitive (core metadata concept) | SNOMED CT core |
| 1479317011 | Tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3534602016 | Tablet (basic dose form) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 13111000188116 | comprimé | fr | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT Switzerland NRC maintained Module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Is a | Type of drug preparation | false | Inferred relationship | Some | ||
| A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Is a | Oral dose form | false | Inferred relationship | Some | ||
| A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Is a | A dose form that displays properties of a solid. | true | Inferred relationship | Some | ||
| A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Has state of matter (attribute) | A state of matter where particles form a stable, definite shape that can only change by force (e.g. break, cut). | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Amylase + lipase + protease 30000unt/8000unt/30000unt tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Amylase + lipase + protease 6000unt/16000unt/6000unt tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Amylase + lipase + protease 8000unt/30000unt/30000unt tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Amylase + lipase, pancreatic + protease, pancreatic 12500unt/1000unt/12500unt tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Aspirin 325 mg and butalbital 50 mg and caffeine 40 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Aspirin 325 mg and carisoprodol 200 mg and codeine phosphate 16 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Aspirin 325 mg and carisoprodol 200 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Aspirin 500 mg and hydrocodone bitartrate 5 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Aspirin 325 mg and meprobamate 200 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Aspirin 325 mg and methocarbamol 400 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely aspirin 325 milligram and oxycodone hydrochloride 2.25 milligram and oxycodone terephthalate 190 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Aspirin 325 mg and oxycodone hydrochloride 4.5 mg and oxycodone terephthalate 380 microgram oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Aspirin + pentazocine hydrochloride 325mg tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Atenolol 100 mg and chlortalidone 25 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Atenolol 50 mg and chlortalidone 25 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely atovaquone 62.5 milligram and proguanil 25 milligram/1 each conventional release oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely atropine 25 microgram and difenoxin hydrochloride 1 milligram/1 each conventional release oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Atropine sulfate 25 microgram and diphenoxylate hydrochloride 2.5 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely atropine sulfate 19.4 microgram and hyoscyamine sulfate 103.7 microgram and scopolamine hydrobromide 6.5 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Azatadine maleate 1 mg and pseudoephedrine sulfate 120 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Benazepril hydrochloride 10 mg and hydrochlorothiazide 12.5 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely bisoprolol 5 milligram and hydrochlorothiazide 6.25 milligram/1 each conventional release oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Captopril 25 mg and hydrochlorothiazide 15 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Captopril 25 mg and hydrochlorothiazide 25 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Captopril 50 mg and hydrochlorothiazide 15 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Carbidopa + levodopa 50mg/200mg m/r tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely carbidopa 10 milligram and levodopa 100 milligram/1 each conventional release oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely carbidopa 25 milligram and levodopa 100 milligram/1 each conventional release oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely carbidopa 25 milligram and levodopa 250 milligram/1 each conventional release oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Chlorothiazide 250 mg and methyldopa 250 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Chlorothiazide 250 mg and reserpine 125 microgram oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely chlorothiazide 500 milligram and reserpine 125 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Chlorpheniramine maleate + methscopolamine nitrate + pseudoephedrine hydrochloride 8mg/2.5mg/120mg m/r tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Chlortalidone 15 mg and clonidine hydrochloride 200 microgram oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely chlortalidone 15 milligram and clonidine hydrochloride 300 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Choline bitartrate 25 mg and dexpanthenol 50 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely clemastine 1.34 milligram and phenylpropanolamine 75 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely dehydrocholic acid 180 milligram and pancreatin 300 milligram and simeticone 40 milligram/1 each conventional release oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Deserpidine 250 microgram and methyclothiazide 5 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely deserpidine 500 microgram and methyclothiazide 5 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing desogestrel 0.15 mg and ethinyl estradiol 0.01 mg/1 each oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing only desogestrel 0.15 mg and ethinyl estradiol 0.03 mg/1 each oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Diltiazem maleate 219 mg and enalapril maleate 5 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely drospirenone 3 milligram and ethinylestradiol 30 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Diprophylline 100 mg and guaifenesin 100 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Diprophylline 200 mg and guaifenesin 200 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| énalapril 10 mg et hydrochlorothiazide 25 mg, comprimé oral | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| énalapril 5 mg et hydrochlorothiazide 12,5 mg, comprimé oral | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Estradiol + estradiol + norgestimate 1mg/1mg/0.09mg tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Estradiol + norethindrone acetate 1mg/0.5mg tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely conjugated estrogen 625 microgram and esterified estrogen 625 microgram and medroxyprogesterone acetate 5 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely esterified estrogen 625 microgram and methyltestosterone 1.25 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely esterified estrogen 1.25 milligram and methyltestosterone 2.5 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Ethinylestradiol 35 microgram and etynodiol diacetate 1 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Ethinylestradiol 50 microgram and etynodiol diacetate 1 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Ethinylestradiol 30 microgram and ferrous fumarate 75 mg and norgestrel 300 microgram oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Ethinylestradiol 20 microgram and levonorgestrel 100 microgram oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely ethinylestradiol 30 microgram and levonorgestrel 50 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely ethinylestradiol 30 microgram and levonorgestrel 125 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Ethinyl estradiol + levonorgestrel 0.03mg/0.15mg tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely ethinylestradiol 40 microgram and levonorgestrel 75 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing only ethinyl estradiol 0.05 mg and levonorgestrel 0.25 mg/1 each oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Ethinylestradiol 35 microgram and norethisterone 400 microgram oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing only ethinyl estradiol 0.035 mg and norethisterone 0.5 mg/1 each oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Ethinylestradiol 35 microgram and norethisterone 1 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Ethinylestradiol 50 microgram and norethisterone 1 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Ethinyl estradiol + norethindrone acetate 20mcg/1mg tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Ethinyl estradiol + norethindrone acetate 30mcg/1.5mg tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Ethinyl estradiol + norgestimate 0.035mg/0.25mg tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Ethinylestradiol 30 microgram and norgestrel 300 microgram oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely ethinylestradiol 50 microgram and norgestrel 500 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Ferrous fumarate 324 mg and folic acid 1 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Guanethidine monosulfate 10 mg and hydrochlorothiazide 25 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Homatropine methylbromide 1.5 mg and hydrocodone bitartrate 5 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydralazine hydrochloride 25 mg and hydrochlorothiazide 15 mg and reserpine 100 microgram oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrochlorothiazide 25 mg and labetalol hydrochloride 300 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrochlorothiazide 25 mg and lisinopril 20 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrochlorothiazide 15 mg and methyldopa 250 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrochlorothiazide 25 mg and methyldopa 250 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrochlorothiazide 30 mg and methyldopa 500 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrochlorothiazide 50 mg and methyldopa 500 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrochlorothiazide 25 mg and propranolol hydrochloride 40 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrochlorothiazide + quinapril hydrochloride 12.5mg/10mg tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely hydrochlorothiazide 12.5 milligram and quinapril 20 milligram/1 each conventional release oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely hydrochlorothiazide 25 milligram and quinapril 20 milligram/1 each conventional release oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrochlorothiazide 25 mg and reserpine 125 microgram oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrochlorothiazide 50 mg and reserpine 125 microgram oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrochlorothiazide 25 mg and spironolactone 25 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrochlorothiazide 12.5mg/telmisartan 40mg tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrochlorothiazide 25 mg and triamterene 37.5 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrochlorothiazide 12.5 mg and valsartan 80 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Hydrocodone bitartrate 7.5 mg and ibuprofen 200 mg oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Isoniazid + pyrazinamide + rifampin 50mg/300mg/120mg tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely levothyroxine sodium 38 microgram and liothyronine sodium 9 microgram/1 each conventional release oral tablet | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely levothyroxine sodium 100 microgram and liothyronine sodium 25 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some | |
| Product containing precisely levothyroxine sodium 12.5 microgram and liothyronine sodium 3.1 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | False | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | Inferred relationship | Some |
Start Previous Page 24 of 28 Next End
This concept is not in any reference sets